Division of PharmaMar SA
Latest From Zeltia SA
European Notebook: Rasi To Review EMA Plans; Spain’s Drug Spend Held Flat By Industry; Insurers Merge In Germany
Re-appointed EMA Executive Director Guido Rasi will outline his plans for the agency in early December; pact in Spain calls for the pharmaceutical industry to reimburse government for spending increases above GDP growth.
Launch of the first FDA-approved subcutaneous allergy vaccine may be four years away, but the European specialty company is starting to plan for commercialization and market growth.
Endocyte and Merck are preparing to launch a combo drug/diagnostic in folate receptor-positive platinum-resistant ovarian cancer, a condition with a very poor survival prognosis, later this year in the EU. Medical affairs staff are meeting with specialists to discuss how the diagnostic can target patients most likely to respond in pre-approval commercial efforts.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions, providing comprehensive transaction coverage from 1991 to the present.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Therapeutic Areas
- Grupo Zeltia
- Western Europe
- Parent & Subsidiaries
- PharmaMar SA
- Senior Management
- J.M. Fernandez Sousa, Pres.
- Contact Info
Phone: (34) 914 444 500
Plaza del Descubridor, Diego de Ordas 3
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.